|
AERES Biomedical develops therapeutic antibodies. The biopharmaceutical research company has developed more than 20 antibody candidates though collaborative partnerships with other biotech and pharmaceutical companies, many of which are in clinical trial stages. ABC-48 (an antibody for the treatment of deep vein thrombosis) and ABC-120 (an antibody for treating malaria) are two of the company's top candiates. AERES' products target debilitating and life-threatening illnesses, such as infectious, inflamatory, and cardiovascular diseases. The company was founded in 1999.
|
| | | Contact Information | |
Address: |
1-3 Burtonhole Lane, Mill Hill
London NW7 1AD, United Kingdom
| | Phone: | +44-20-8906-7222 | | Fax: | +44-20-8906-7201 |
|
| Financial
Highlights | | Fiscal Year End: | March |
|
|
Key People
| | • |
Chairman:
David Owen
| | • |
CEO and Chief Scientific Officer:
Tarran Jones
| | • |
COO and CFO:
David Copsey
|
|
|
